What is AnaBios?
AnaBios operates at the intersection of biotechnology and clinical research, specializing in the validation of novel compounds through human-centric translational models. The company addresses critical therapeutic gaps in areas such as cardiac disease, chronic pain, and dermatological conditions. By integrating its internal drug discovery platform with in-licensed programs, AnaBios provides a comprehensive suite of services that enhance the safety and efficacy profiles of new therapeutics. Its market position is fortified by a unique business model that serves both as a high-end service provider for CROs and a developer of its own internal pipeline, effectively diversifying its revenue streams and risk profile within the competitive biotech landscape.
How much funding has AnaBios raised?
AnaBios has raised a total of $12.3M across 3 funding rounds:
Series A
$2M
Series B
$10M
Debt
$350K
Series A (2011): $2M with participation from Tech Coast Angels
Series B (2016): $10M led by Principia SGR
Debt (2020): $350K supported by PPP
Key Investors in AnaBios
Principia SGR
A prominent Italian venture capital firm managing specialized funds, including Principia III-Health, which focuses exclusively on the healthcare sector and early-stage medical innovation.
Tech Coast Angels
One of the largest and most active angel investor networks in the United States, providing early-stage capital and mentorship to high-growth technology and life science startups.
PPP
Public-Private Partnership
What's next for AnaBios?
Looking ahead, the recent capital injection is expected to accelerate the expansion of the company's internal drug discovery pipeline and enhance its translational technology infrastructure. As AnaBios continues to scale, the focus will likely shift toward deepening its partnerships with global pharmaceutical leaders and optimizing its proprietary human-tissue-based testing methodologies. The strategic deployment of these funds will be instrumental in navigating the complexities of late-stage drug development, ensuring that the company remains at the forefront of precision medicine and therapeutic innovation. By maintaining its commitment to high-quality, human-focused data, AnaBios is well-positioned to capitalize on the growing demand for more reliable preclinical models in the global healthcare market.
See full AnaBios company page
